Lilly sinks $20M into Chinese firm for 'branded generic' drugs

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co. has invested $20 million in a Chinese pharmaceutical company in an effort to build up a portfolio of branded generic medicines in the fast-growing Asian market.

Indianapolis-based Lilly already held an unspecified equity stake in Novast Laboratories Ltd., which manufactures specialty and generic drugs from its headquarters in Nantong, a short distance north of Shanghai. It announced the new investment Tuesday.

Lilly intends to work with Novast to develop a catalog of generic versions of medicines not created by Lilly that will be branded with the Lilly name. Such a category of drugs—which is rare in the United States—is an important class of drugs in China.

That’s because brand-name drugs have social cache among wealthy Chinese, in a similar way that luxury cars, watches or handbags do in the United States. Sanjay Behl, a pharmaceutical consultant at Deloitte Consulting, said it’s common at cocktail parties in China to hear people talk about the brand of the medicines they’re taking.

Lilly also hopes that by branding a generic drug with the Lilly name, Chinese customers will view it as a mark of quality.

Both factors allow Lilly to earn higher profit margins on branded generics than fully generic drugs, although the margins are still lower than what Lilly earns on its own pipeline of drugs.

"In Lilly's emerging markets business, we are focused on providing patients with innovative medicines from our own pipeline, as well as select Lilly branded generic medicines that meet our quality standards,” said Jacques Tapiero, Lilly’s president of emerging markets, in a prepared statement.

Down the road, Novast also may take on manufacturing responsibilities for new drugs Lilly launches in China and other Asian countries. Since 2009, Lilly has rapidly ramped up sales and research functions in China, and now employs more than 3,000 people there.

In June, Lilly announced the opening of a new research and development center in China focused exclusively on diabetes. It employs a staff of 150.

Lilly's sales in China have been modest but growing fast. They increased 31 percent in China last year, according to Lilly officials, to nearly $420 million.

"This long-term strategic partnership will combine Lilly's expertise in innovation, commercialization and operations with Novast's strengths in product development and quality manufacturing," Novast CEO Dr. Guohua Zhang said in prepared statement. "We are committed to helping Lilly bring high-quality medicines to patients in China and potentially other countries.”

Lilly first invested in Novast after establishing a $100 million Asian venture fund five years ago. The amount of Lilly’s initial investment has not been disclosed. But Lilly officials said they planned to plow the money into 12 to 15 companies.


Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ
  1. How much you wanna bet, that 70% of the jobs created there (after construction) are minimum wage? And Harvey is correct, the vast majority of residents in this project will drive to their jobs, and to think otherwise, is like Harvey says, a pipe dream. Someone working at a restaurant or retail store will not be able to afford living there. What ever happened to people who wanted to build buildings, paying for it themselves? Not a fan of these tax deals.

  2. Uh, no GeorgeP. The project is supposed to bring on 1,000 jobs and those people along with the people that will be living in the new residential will be driving to their jobs. The walkable stuff is a pipe dream. Besides, walkable is defined as having all daily necessities within 1/2 mile. That's not the case here. Never will be.

  3. Brad is on to something there. The merger of the Formula E and IndyCar Series would give IndyCar access to International markets and Formula E access the Indianapolis 500, not to mention some other events in the USA. Maybe after 2016 but before the new Dallara is rolled out for 2018. This give IndyCar two more seasons to run the DW12 and Formula E to get charged up, pun intended. Then shock the racing world, pun intended, but making the 101st Indianapolis 500 a stellar, groundbreaking event: The first all-electric Indy 500, and use that platform to promote the future of the sport.

  4. No, HarveyF, the exact opposite. Greater density and closeness to retail and everyday necessities reduces traffic. When one has to drive miles for necessities, all those cars are on the roads for many miles. When reasonable density is built, low rise in this case, in the middle of a thriving retail area, one has to drive far less, actually reducing the number of cars on the road.

  5. The Indy Star announced today the appointment of a new Beverage Reporter! So instead of insightful reports on Indy pro sports and Indiana college teams, you now get to read stories about the 432nd new brewery open or some obscure Hoosier winery winning a county fair blue ribbon. Yep, that's the coverage we Star readers crave. Not.